Epeius Biotechnologies Initiates Tri-REX Vaccination Protocols For Breast Cancer

Epeius Biotechnologies today announced the opening of a Vaccine-assisted
Phase I/II clinical trial for metastatic breast cancer that is refractory
to conventional chemotherapy. The innovative protocol introduces
Reximmune-C(TM), the second in a series of targeted biologic therapies
designed to seek out, accumulate in, and destroy metastatic tumor nodules,
while sparing normal cells and tissues. The lead product, Rexin-G(TM), has
recently been granted Orphan Drug Status by the FDA.


*(LOGO: Send2Press/mediadesk/logo-epeius_72dpi.jpg)
Based on "Pathotropic" (disease-seeking) targeting technologies
developed at the University of Southern California School of Medicine and
Childrens Hospital Los Angeles, these targeted biologics are designed to
operate within the human circulatory system to deliver genetic medicine
precisely where it is needed. The new Tri-REX Vaccination Protocol for
Breast Cancer involves (1) the targeted delivery of a cancer-killing
designer gene to reduce the tumor burden, followed by (2) the targeted
delivery of a powerful immune activating gene, followed by (3) a repeat of
the cancer-killing cycle in order to generate additional tumor debris and
present tumor antigens to the now-activated and localized immune cells.


The new Tri-REX Therapeutic Vaccination Protocol stems from direct
observations in previous clinical trials that Rexin-G(TM), not only
accumulates in primary tumors and metastatic sites, but also drains, like
metastatic tumor cells, into sentinel lymph nodes where the therapy remains
biologically active and tumoricidal. The demonstrations of dead and dying
cancer cells in cancerous lymph nodes following Rexin-G(TM) infusions in
pancreatic cancer, breast cancer, and malignant melanoma patients open up
an opportunity for targeted autovaccination to encourage the patient's
immune system to participate in the tumor eradication and to lower the
incidence of recurrence.


According to Dr. Frederick L. Hall, Chief Scientific Officer of Epeius
Biotechnologies: "This approach to therapeutic vaccination is likely to
succeed where many, as in many, have failed. You see, biologic targeting is
the key: the key to efficient gene delivery in the body, the key to
effective cancer therapy, and the key to successful cancer vaccinations."


This month, the Tri-REX Vaccination Protocol will be tested on a
limited number of patients in Manila in a Phase I/II clinical trial
sponsored by Epeius Biotechnologies.


This release was issued on behalf of the above organization by
Send2Press(R), a unit of Neotrope(R). send2press


Epeius Biotechnologies Corporation

send2press

Buy Kenalog Without Prescription